Since October of last year, the Hong Kong stock market's pharmaceutical sector has undergone a significant correction. Initially, this downturn was primarily driven by waning market sentiment and Bio-pharma Deals (BD) falling short of expectations. In the latter stages, it was further exacerbated by a systemic decline in the broader Hong Kong market, leading to a catch-up drop for the sector. This process has resulted in a relatively thorough release of risk within the Hong Kong pharmaceutical sector. Consequently, against the backdrop of recent heightened market volatility, Hong Kong pharmaceutical stocks have become a key destination for capital rotation. Observations indicate that since its rebound began on March 24th, the Hang Seng Healthcare Index has accumulated a gain of 17.5%. This rebound has lifted many stocks that had previously experienced significant declines, with ASCLETIS-B being one of them.
Following a peak of HKD 18.64 on February 11th, ASCLETIS-B's share price underwent a pronounced correction, hitting a low of HKD 12.68 during trading on March 23rd, representing a maximum decline of over 30% during that period. Benefiting from the broader index rebound, ASCLETIS-B's share price gradually climbed, reaching HKD 18.68 during trading on April 17th, coming within close reach of its previous high of HKD 18.75 from August of last year. With the share price on the verge of breaking through this previous high, why are investors outside the market choosing to adopt a wait-and-see approach?
Analyzing this rebound in the Hong Kong pharmaceutical sector reveals that the rise in innovative drug stocks is not merely a short-term, sentiment-driven spike. Instead, it is the result of a confluence between a short-term rebound window and a long-term industry inflection point. From a long-term perspective, the core drivers for the industry remain intact and are strengthening: the number of BD transactions for Chinese innovative drug firms listed in Hong Kong, along with their global share and penetration rate, are projected to rise rapidly by 2025. It is estimated that by 2025, Chinese innovative drug BD deals will account for approximately 15% of the global total by number and over 20% by value. Furthermore, in the first quarter of 2026, the total value of China's out-licensing BD transactions surpassed $60 billion, nearly half of the $135.7 billion total for the entire year of 2025. This indicates that for the innovative drug sector, the "going global" narrative has transitioned from a short-term theme to a long-term trend.
The recent 2025 earnings season also demonstrated that several leading Hong Kong-listed innovative drug companies, leveraging years of pipeline development and stable revenue from commercialized products, coupled with consistent cash flow from BD deals, have effectively covered R&D expenditures. This has led to a significant improvement in cash flow and substantial profit growth. As these leading companies enter a phase of delivering on their earnings potential, the market's pricing logic has shifted from speculating on left-side expectations to verifying right-side performance, which is a key rationale behind the current sector rebound.
However, this is not a blanket profitability story across the entire industry. Statistics show that among 79 Hong Kong-listed biotech companies, only 27 reported positive net profits attributable to shareholders, highlighting a clear structural divergence within the sector. While leading firms are beginning to realize returns on innovation, many small and mid-sized pharmaceutical companies remain in high-investment R&D phases, where substantial expenditures have not yet translated into scaled commercial value.
Returning to ASCLETIS-B, its recent price rebound can be divided into two distinct phases: the first from March 24th to March 30th, and the second from March 31st to the present. In the first phase, the stock's rise was primarily driven by a "technical rebound from oversold conditions." Prior to March 24th, ASCLETIS-B's share price had experienced a deep correction, falling over 30% at its lowest point. Notably, from March 11th to March 23rd, the stock recorded nine consecutive days of decline. After a high-volume drop on March 23rd, trading volume plummeted to just 854,400 shares the following day, with the RSI indicator hitting a low of 13.76. This suggested extreme selling pressure and potential seller exhaustion. At this point, the convergence rate of the 70% and 90% cost concentration ratios reached 78.17%, indicating a high degree of control by major holders. Consequently, on March 24th and 25th, the stock rose 5.34% and 4.56% respectively on very low volumes of 854,400 shares and 1.244 million shares. A significant "volume-price surge" occurred only on March 26th, when the stock price jumped 12.67% accompanied by a trading volume of 9.218 million shares.
However, after ASCLETIS-B released its 2025 financial results on March 30th, the secondary market reacted with three consecutive days of decline, slowing the upward momentum. From a performance standpoint, the company reported a net loss that widened by 19.6% year-over-year, despite revenue of CNY 127 million. From a volume perspective, after the surge on March 26th, daily trading volume noticeably contracted. Over the following 13 trading days, volume exceeded 3 million shares on only four occasions. This price increase on low volume suggests that even as the share price approached its previous high, potential buyers remained cautious, showing limited willingness to chase the rally.
The primary reason for ASCLETIS-B's "increased revenue but not profit" in 2025 was a sharp rise in R&D expenses. Data shows the company's R&D expenditure reached CNY 409 million, a significant increase of 35.3% year-over-year. Furthermore, despite holding CNY 1.93 billion in cash, the company completed a new share placement in February, raising net proceeds of HKD 835 million, with 90% of these funds directly allocated to the global Phase III clinical trial for its GLP-1 candidate. In short, ASCLETIS-B's current strategy is a high-stakes bet on the weight-loss drug market, aiming to propel its core candidate into the final global competitive stage.
For ASCLETIS-B, this is undoubtedly a high-risk, high-reward strategy. The company's confidence in this "all-in" approach stems from its core GLP-1 candidate, ASC30, an oral small molecule full GLP-1 receptor agonist. Currently, there are two main technological paths for oral GLP-1 drugs: peptides and small molecules. Compared to oral peptides like semaglutide, oral small molecules like orforglipron are generally considered to have advantages in pharmacokinetics, administration, and manufacturing. The high hopes for ASC30 lie in its Best-in-Class potential: it demonstrates stronger agonist activity and higher in vivo exposure compared to orforglipron. Both ASC30 and orforglipron are GLP-1 receptor agonists. Head-to-head cell studies indicate that ASC30's cAMP agonist activity is approximately twice that of orforglipron. Additionally, pharmacokinetic data from human Multiple Ascending Dose studies show that at similar doses, ASC30's in vivo exposure is about 2.3 times higher than orforglipron's. Previous Phase IIa clinical studies suggested that ASC30 maintains leading efficacy within its class, with a potentially more prominent safety profile, which is crucial for longer-term studies and real-world application post-approval.
However, a challenge for ASC30 is the increasingly competitive landscape of oral small molecules targeting the Lilly framework. ASC30 is currently positioned in the global second tier. Incomplete statistics indicate there are about 10 oral small molecules in clinical development globally targeting this mechanism, with several early-stage candidates advancing, intensifying competition. Moreover, according to recent information, Lilly's orforglipron received FDA approval on April 1st, making it the world's first oral small molecule non-peptide GLP-1 drug for weight loss. Citigroup research forecasts peak sales for orforglipron could exceed $40 billion and suggests Lilly faces little competition in the oral small molecule GLP-1 space for the next three years. This means the commercial pressure on ASC30 and other oral small molecules targeting the Lilly framework is mounting following orforglipron's approval. While ASC30's core advantages lie in oral convenience, dosing frequency, and patient tolerability, from a commercialization perspective, both Lilly's sales capabilities and orforglipron's first-mover advantage present significant hurdles for ASCLETIS-B and ASC30 to overcome in the short term.
Returning to the secondary market, propelled by the earlier oversold rebound, ASCLETIS-B's share price is tantalizingly close to its previous high. However, the proportion of profitable holdings has reached an extremely high 99.53%, indicating significant risk for those considering buying at current levels. Furthermore, with the RSI indicator again approaching 80, short-term overbought signals are emerging. Against this backdrop, the extent of further near-term upside for ASCLETIS-B's share price remains uncertain.
Comments